Responsibilities
In collaboration with the Discovery team, build and apply cheminformatics and computational chemistry capabilities to support the Design‑Make‑Test‑Analyze (DMTA) discovery cycle in radiotheranostics.
Contribute to the advancement of the radiotheranostic pipeline by applying computational approaches such as molecular docking, ligand‑based design, diversity and conformational analyses, together with machine learning and AI methods, to support multiparameter optimization of radioligand candidates.
Develop, optimise, and implement computational tools, workflows and methods (e.g. docking, molecular dynamics, free‑energy calculations, ML/AI‑assisted design) to strengthen internal discovery capabilities and accelerate project progression.
Provide computational support and scientific input across key discovery stages, including target assessment, hit identification and lead optimisation, working closely with medicinal chemistry and biology teams.
Collaborate with the IT and data science teams to integrate AI‑enabled tools into day‑to‑day drug design workflows.
Clearly communicate computational results, design hypotheses and data‑driven recommendations to multidisciplinary project teams.
The position will be based in Chatillon; in March the site is scheduled to move to Villejuif.
About Orano Med
Orano Med is a biotechnology company owned by Orano, dedicated to developing a new generation of targeted cancer therapies using the unique properties of lead‑212, a rare alpha‑emitting radioisotope with highly promising medical properties. Orano is an international operator in the field of nuclear materials, providing solutions in energy and health, and is committed to innovation, safety and excellence.
#J-18808-Ljbffr